Avastin Biosimilars - Target Pipeline List 11/2018
Delivery costs do not apply or are included.
Ask a question about this product
Avastin Biosimilars – Target Pipeline List 11/2018
Target: Vascular Endothelial Growth Factor (VEGF)
This report provides a comprehensive overview of biosimilars of the recombinant humanized monoclonal antibody Avastin (bevacizumab) from Roche in regulated and in less regulated markets for treatment of solid tumors, including metastatic colorectal cancer, non-squamous non-small cell lung cancer, glioblastoma, renal cell carcinoma, cervical cancer, ovarian, fallopian tube and peritoneal cancer.
Avastin is one of Roche’s best selling cancer antibodies with global sales of CHF 6.688 bln (about US$ 6.708 bln as of Nov 23, 2018). While the US patent on Avastin (bevacizumab) expires in 2019, the drug’s main European patent expires in 2022.
The first Avastin biosimilar developed in regulated markets has already been approved by the European Commission and by the US FDA. In less regulated markets, at least six biosimilar versions of Avastin are already on the market.
La Merie Publishing offers a low-cost product service providing information about active R&D projects for a given target in the format of Word tables. The Word document with the Table is delivered by e-mail within 24 hours after receipt of the confirmed order. Usually, delivery time is less than one hour if ordered during European business hours.
The Target Pipeline List in the Word table contains information about:
File: ID no. in proprietary database
Drug name: trade name, INN, drug code(s), trivial name
Target/MoA: mechanism of action
Class of compound: description of type of molecule, formulation, way and mode of administration, application device
Company: originator of molecule and licensee(s) with territories
Category: treatment modalities, i.e. antibody, protein, peptide, RNA, DNA, cells, vaccine, small molecule
Indication: medical indication evaluated in preclinical or clinical study, combination regimens
R&D Phase: from research to market with reference to indication/study
Message: last verified information about project with source and date of information and hyperlink leading to source of information
Information about R&D projects is identified and retrieved from company publications including, but not limited to, press releases, presentations, website disclosures, SEC publications, regulatory documents, scientific abstracts and full papers, patent applications. Furthermore, public and proprietary databases are used including national and regional clinical trial databases, PubMed.